A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication

Area of Science:

• Chemical biology
• Hepatology
• Virology

Background:

• Chronic hepatitis C virus (HCV) infection has limited treatment options with suboptimal response rates.
• Current therapies like pegylated-interferon and ribavirin cause significant side effects.
• There is a critical need for novel, well-tolerated agents to combat HCV infection.

Purpose of the Study:

• To apply chemical biology approaches to screen for small molecules that modulate HCV replication.
• To identify novel antiviral and proviral agents targeting HCV.
• To investigate the role of lipid metabolism and corticosteroids in the HCV life cycle.

Main Methods:

• Optimization of a Huh7/Rep-Feo replicon cell line for high-throughput screening (HTS) in a 384-well microplate format.
• Screening of a large library of known biologically active compounds using automated technology.
• Validation of hit compounds using a full-length HCV replicon cell line in secondary screens.

Main Results:

• Identification and validation of HMG-CoA reductase inhibitors as potent antiviral agents against HCV.
• Discovery of corticosteroids as proviral agents that enhance HCV replication, independent of immune suppression.
• Evidence suggesting a significant role for lipid metabolism in the HCV viral life cycle.

Conclusions:

• Development of a robust, reproducible, and reliable cell-based HTS assay for identifying HCV replication modulators.
• The screening system can identify potential antiviral drugs and cellular factors influencing viral replication.
• Findings provide new avenues for therapeutic strategies targeting HCV through modulation of lipid metabolism.